Alexion To Pay $25M To Settle Soliris Suit
Under the settlement reached in late December, Alexion confirmed that its drug uses technology covered under PDL’s patents, and PDL agreed not to sue Alexion over other claims of the patents, clearing the way for Alexion to continue to commercialize Soliris.
The companies said the agreement wraps up PDL’s suit filed in March...
Already a subscriber? Click here to login